Nexentis Technologies Files Prospectus For Offering 2.573M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1789192/000149315226033026/forms-1.htm
Read original at benzingaStocks · News reference
Nexentis Technologies Subsidiary MitoCareX Bio Narrows Its SLC Transport Protein Candidates To Select Candidate For A Drug Discovery Campaign
As previously disclosed, MitoCareX's broad structural analysis identified a set of SLC transport proteins outside its mitochondrial program that appeared compatible with the MITOLINE® enabled structural modelling.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 12:13 PM
- Checked
- Jul 28, 2026, 12:13 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Nexentis Technologies Subsidiary Completes Analysis Of SLC Transport Proteins, Starts Global AI Drug Discovery Initiative With Boltz
Read original at benzingaNexentis Technologies Amends Its Loan And Partnership Agreement With Solterra Renewable Energy, Other Lenders For Melz Solar Project; Solterra To Make Early Partial Repayments Of ~$147K On Its Part Of Loan, $98K For Sale Of 10% Of Its Profit Rights;
Read original at benzinga